Upregulation of glucose and amino acid transporters in micropapillary carcinoma

Authors: Kanae Nosaka, Karen Makishima, Tomohiko Sakabe, Yohei Yurugi, Makoto Wakahara, Yasuaki Kubouchi, Yasushi Horie and Yoshihisa Umekita

DOI: 10.14670/HH-18-099
Article type: ORIGINAL ARTICLE
Accepted: 2019-03-11
Epub ahead of print: 2019-03-11

This article has been peer reviewed and published immediately upon acceptance.
Articles in “Histology and Histopathology” are listed in Pubmed.
Pre-print author’s version
Upregulation of glucose and amino acid transporters in micropapillary carcinoma

Kanae Nosaka, Karen Makishima, Tomohiko Sakabe, Yohei Yurugi, Makoto Wakahara, Yasuaki Kubouchi, Yasushi Horie, Yoshihisa Umekita

1Division of Organ Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Tottori, Japan
2Department of Pathology and 3Department of General Thoracic Surgery, Tottori University Hospital, Tottori, Japan

Running title: Transporters in micropapillary carcinoma

*Corresponding author: Dr. Kanae Nosaka, Division of Organ Pathology, Department of Pathology, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan. Email: knosaka@tottori-u.ac.jp
Summary

Micropapillary carcinoma (MPC), a relatively rare histologic carcinoma observed in various organs, is associated with vascular invasion, nodal metastasis, and poor prognosis. MPC is different from papillary carcinoma as it has no fibrovascular core and is thus considered essentially hypovascular. MPCs are known to upregulate glucose transporter 1 (GLUT1) via the activation of a transcription factor, hypoxia-inducible factor (HIF)-1. Here we evaluated the expression of nutrient transporters in MPCs to gain a better understanding of the system used by MPCs to compensate for their intrinsic poor vascularity. We immunohistochemically evaluated 29 MPCs including breast (n=14), lung (n=8), gastrointestinal tract (n=5), and urinary tract cancers (n=2) and compared them with non-micropapillary control cancers (n=32) regarding the expression of amino acid (ASCT1, ASCT2, LAT1, and SNAT1) and glucose (GLUT1, GLUT2) transporters. Each section was scored by the staining intensity (0–3) multiplied by the occupying area (0–10), with a possible range 0–30. The average scores of the MPC and control groups were compared by Student's or Welch's t-test according to the homoscedasticity. The MPC group showed markedly and significantly higher scores for ASCT1 (p=0.007), ASCT2 (p=0.001), GLUT1 (p<0.001), and GLUT2 (p<0.001), whereas no significant between-group difference was observed in the LAT1 and SNAT1 scores. In conclusion, MPC could be associated with the upregulation of several nutrient transporters, which may contribute to the malignant potential by supporting the survival of cancer cells.
Key words: micropapillary carcinoma, GLUT1, GLUT2, ASCT1, ASCT2, LAT1, SNAT1, hypoxia
Introduction

Since the first report by Luna-Moré et al. in 1994, micropapillary carcinoma (MPC) or micropapillary components in several cancers have been a well-known risk factor for blood and/or lymph vessel invasion, lymph node metastasis, and mortality (Nagano et al., 2010; Willis et al., 2014; Lee et al., 2015; Liu et al., 2015). MPCs have been documented in the breast, the lung, the gastrointestinal (GI) tract, and the urothelial cancers, where the presence of MPC is nearly always a sign of poor prognosis (Guzińska-Ustymowicz et al., 2014; Zhang et al., 2015). By definition, an MPC forms delicate papillary tufts devoid of central fibrovascular cores, which makes these papillary tufts different from "true" papillae with cores. Micropapillae are occasionally floating in the lacunar-like space in the fibrous stroma with their apical surfaces outwards; this is known as the "inside-out" growth pattern (Troxell, 2014).

For cancers to progress, vascularity within or around the tumor is thought to be important, since proliferating cancer cells need large amounts of nutrients (Carmeliet and Jain, 2000). MPCs are suspected to be always under a condition of poor nutrition and hypoxia due to their lack of a fibrovascular core (Nagano et al. 2010). However, MPCs are a highly aggressive cancer, and their massive necrosis is rarely observed. We speculated that MPCs have evolved some compensatory system(s) against the poor blood and nutrition supply, and that such compensatory system(s) may contribute to the aggressive behavior and poor prognosis of MPCs.
Glucose transporter 1 (GLUT1), a major glucose transporter of somatic cells, has been shown to be upregulated in MPCs via the activation of the transcription factor hypoxia-inducible factor (HIF)-1 (Nagano et al., 2010; Koh et al., 2017). HIF-1 controls the angiogenesis and accommodation of various cellular activities to hypoxia (Wang and Semenza, 1993; Carmeliet and Jain, 2000). GLUT1 is a representative HIF-1 target gene product. An upregulation of GLUT1 can substantially improve the uptake of glucose, and it supports energy production via accelerated glycolysis. Proliferating cancer cells also require building blocks such as amino acids and lipids other than sugar and oxygen, and several amino acid transporters are known to be upregulated in various cancers (Yanagida et al., 2001; Fuchs and Bode, 2005; Kaira et al., 2009; Fan et al., 2010).

However, the differences in amino acid transporter expression among different carcinoma histologic subtypes have not been fully examined. We hypothesized that MPCs may compensate for their poor vascularity via upregulations of amino acid and sugar transporters such as alanine-serine/cysteine/threonine transporter 1 (ASCT1), ASCT2, L-type amino acid transporter 1 (LAT1), sodium-coupled neutral amino acid transporter 1 (SNAT1), GLUT1, and GLUT2 with more significant augmentation compared to non-MPC cancers, which leads to the MPCs' aggressiveness.
Materials and Methods

Case selection

We retrospectively analyzed surgically resected specimens that had been histologically diagnosed as MPCs or as carcinomas with MPC components at the Department of Pathology, Tottori University Hospital (Yonago, Japan) during the years 2004–2016, regardless of the patients' age, sex or tumor stage (Table 1). Small cancers with an invasion diameter <1 cm and mixed MPC component <10% were excluded. Cases with suspicious antigen degeneration (e.g., insufficient staining of inner positive controls in an immunohistochemical procedure) were also excluded. The final total of 29 MPC cases included 14 breast cancers, 8 lung cancers, 5 gastrointestinal (GI) cancers, and 2 urothelial cancers. Five of the breast cancers were pure MPCs, and the remaining 24 MPCs were mixed cancers with conventional histological subtypes. We also selected 32 control cases from the above-mentioned organs. Control cases of lung adenocarcinoma were selected in order to not deviate from the specific histological subtype.

Written informed consent for their materials to be used was obtained from each patient, and the study was approved by the Ethics Committee of the Faculty of Medicine, Tottori University (approval no. 1707A071; July 13, 2017).
Immunohistochemistry and scoring

The primary antibodies used in this study are listed in Table 2. The upregulation of all of the target transporters in cancers has been reported. Paraffin-embedded formalin-fixed tissue of the cancers were cut into 4-µm slices and placed on silane-coated glass slides. After being baked at 70°C for 30 min, the sections were deparaffinized and hydrated in xylene and a concentration-gradient ethanol-water system. Endogenous peroxidase activity was quenched in 30% aqueous H₂O₂ with methanol (10% v/v). Sections were heated to 95°C in pH 6.0 citrate buffer for 20 min for antigen retrieval, then cooled to room temperature. After blocking with Block Ace solution (4 g/100 ml; DS Pharma Biomedical, Osaka, Japan), the sections were incubated with each primary antibody at 4°C overnight.

After being washed with phosphate-buffered saline (PBS) containing Tween, the slides were incubated with secondary antibody (EnVision Dual link system; Dako, Glostrup, Denmark) for 30 min. Antigen-antibody complex was visualized by a Liquid DAB+ Substrate Chromogen System (Dako), then counterstained with hematoxylin.

For a quantitative evaluation of the expression of each transporter, every slide was scored based on its average staining intensity (1: weak, 2: moderate, 3: strong) multiplied by the positive ratio per tumor area (0: 0%, 1: 1%–10%, 2: 11%–20%, 3: 21%–30%, 4: 31%–40%, 5: 41%–50%, 6: 51%–60%, 7: 61%–70%, 8: 71%–80%, 9: 81%–90%, 10: 91%–100%), resulting in a score from 0 to 30. For the MPC cases, only the MPC components were evaluated, and for the non-MPC cases (CONT), all the cancer areas were evaluated. Two
pathologists (KN and KM) scored the slides individually, and the similarity of the scores by
the two observers was statistically confirmed. KM was blinded to the purpose of this study
while scoring.

Statistical analyses

We first examined the homoscedasticity of the score distribution in the MPC and
control groups by using the Levine test. If the score distribution was found to be
homoscedastic, the average scores of the MPC versus control cases were compared with
Student's t-test. When the distribution was not homoscedastic, the average scores were
compared with Welch's t-test. The difference was considered significant when $p<0.05$. The
Statistical Package for Social Sciences ver. 24 (IBM SPSS Statistics; IBM, Armonk, NY) was
used in all statistical analyses.

Results

The staining patterns of the transporters

Representative staining patterns of the respective transporters are shown in Figure 1.

ASCT1 showed a linear staining pattern on the basolateral membrane. Weak to moderate
cytoplasmic staining was often observed. Plasma cells served as inner positive controls.

ASCT2 showed fine granular cytoplasmic staining with faint membranous staining.

Adipocytes served as inner positive controls.
GLUT1 showed intense membranous staining. Erythrocytes served as inner positive controls. GLUT2 showed only a finely granular cytoplasmic staining pattern, in contrast to the membranous staining of hepatocytes in our examination determining the optimal conditions for staining. LAT1 showed a linear staining pattern along the basolateral membrane. Vascular smooth muscle cells served as inner positive controls. SNAT1 showed a coarse granular cytoplasmic staining pattern. In the breast cancers, non-neoplastic ductal epithelium served as inner positive controls.

The staining scores of the MPC vs. control cases in the respective organs

The staining scores of the MPCs and control cases are summarized in Table 3. The ASCT1, ASCT2, GLUT1, and GLUT2 scores were significantly higher in the MPC group. No significant difference was revealed in the LAT1 or SNAT1 scores (Fig. 2).

Discussion

GLUT1 upregulation was predictable considering MPCs' intrinsic hypoxia due to a structural factor. Higher GLUT1 expression in MPCs was histologically confirmed in lung adenocarcinomas (Nagano et al., 2010; Koh et al., 2017), and a facilitated uptake of 2-\(^{18}\)fluoro-deoxy-D-glucose (\(^{18}\)FDG) by lung MPCs on positron emission tomography has also been reported (Nakamura et al., 2015). Our present findings indicate that the augmented expression of GLUT1 in MPC is an almost universal event, not restricted to lung cancer.
GLUT2 is a glucose and fructose transporter with high capacity and low affinity that is thought to act as a glucose sensor molecule of hepatocytes and islet β cells of the pancreas. GLUT2 is also thought to facilitate glucose absorption at the small intestine when the glucose level is significantly elevated, e.g., after a meal (Mueckler and Thorens, 2013). GLUT2 is also known to act as a glucosamine transporter (Uldry et al., 2002), but it is unclear whether this role is beneficial to MPC. Although GLUT2 upregulation in pancreatic and liver cancers is well known, its overexpression in cancers in extra-hepatobiliary organs has not been well investigated (Godoy et al., 2006; Kim et al., 2017). It is intriguing that GLUT2 is usually detected in the cancer cell cytoplasm and not as the membranous staining of normal control cells such as human hepatocytes. It is reported that insulin internalizes membrane-bound GLUT2 to the cytosol (Tobin et al., 2008). Whether this membrane-to-cytoplasm translocation of GLUT2 has some relation to cancer activities remains to be solved.

Several amino acid transporters such as ASCT2 and LAT1 are often upregulated in cancers (Yanagida et al., 2001; Fuchs and Bode, 2005; Kaira et al., 2009; Fan et al., 2010; Wang et al., 2013). In fact, in the present study the scores for the ASC transporters (ASCT1, ASCT2) were markedly higher in the MPC group. ASCT2, a gene product of SLC1A5, is a member of the ASC system which transports neutral amino acids such as Ala, Ser, Cys, and glutamine (Fuchs and Bode, 2005). This transporter is thought to be controlled by another hypoxia-sensing factor (HIF2α) to some extent, via a transduction pathway using lactate as a signal molecule (Pérez-Escuredo et al., 2016). ASCT2 upregulation may thus be reasonable in
hypoxic and presumably glycolysis-dependent MPCs.

LAT1 is known to be overexpressed in many cancers (Yanagida et al., 2001; Kaira et al., 2009; Fan et al., 2010), and its overexpression correlates with worse prognosis. However, no significant difference in the expression of LAT1 was demonstrated in the present study. Although SNAT1 is thought to have a critical role in cancers (Wang et al., 2013), no significant difference in the SNAT1 score was demonstrated herein. These transporters' overexpression may be related to the cancer activity itself and have no association with MPCs' structure or their compensatory system.

Our present findings suggest that MPCs can efficiently compensate for their hypoxia and poor nutrition by upregulating several nutrient transporters, and the hypoxia itself can be quite beneficial for the MPCs' utilization of nutrients from the environment. In addition, the cell division of MPCs has been suggested to be less active compared to other histological subtypes (Ishii et al., 2011; Zhang et al., 2015), which may make MPCs more "economic," enabling them to survive severe conditions until they reach a more suitable field for tumor growth. However, an immunohistochemical analysis is merely a subjective assessment, and we examined a relatively small number of cases in the present study. Objective evaluations using molecular biological approaches with larger collections of MPC cases are needed.

In conclusion, this is the first study to investigate the difference in the metabolic state of cancers, focusing on MPC, a specific histological subtype. We speculate that respective histological subtypes may differ not only in proliferation and/or invasion activity, but also in
oxygenation, nutrition, and secondary compensatory systems. Our present findings also
demonstrate an example of cancer cell accommodation to the environment. Closer
investigations of the relationship between histological subtypes and metabolic states will lead
us to a better understanding of complex cancer behavior and more effective anti-cancer
strategies.

Acknowledgements

We thank Dr. Takashi Ohno, Dr. Yoshiteru Kidokoro, and Dr. Taichi Kadonaga (Tottori
University Hospital, Japan) for providing surgical and clinical knowledge. We also thank Ms.
Yuko Urakami for her excellent technical assistance with the pathological specimens'
processing.

Author contributions

KN designed the study. KM and TS conducted the validation analysis. YY and MW reviewed
the cases and provided the clinical information. YK prepared recent specimens for this study.
All pre-2014 cases were diagnosed by YH. KN and YU analyzed the data and wrote the
manuscript. All authors read the manuscript and approved its submission.
Conflict of interest

The authors confirm that there are no conflicts of interest.

References


Diabetes. 57, 555-562.


gastric adenocarcinoma: An aggressive variant associated with poor prognosis. Gastric Cancer. 18, 93-99.
<table>
<thead>
<tr>
<th></th>
<th>Case No.</th>
<th>M/F</th>
<th>Age, yrs</th>
<th>Cases with positive LN metastasis (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPC</td>
<td>14</td>
<td>0/14</td>
<td>66.1/67±16.9</td>
<td>8/14 (57.1)</td>
</tr>
<tr>
<td>Control</td>
<td>15</td>
<td>0/15</td>
<td>62.3/59±14.5</td>
<td>2/15 (13.3)</td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td>15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPC</td>
<td>8</td>
<td>6/2</td>
<td>68.4/71±7.5</td>
<td>2/8 (25)</td>
</tr>
<tr>
<td>Control</td>
<td>7</td>
<td>4/3</td>
<td>68.7/70±10</td>
<td>3/7 (42.9)</td>
</tr>
<tr>
<td><strong>GI</strong></td>
<td>10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPC</td>
<td>5</td>
<td>4/1</td>
<td>66.0/66±6.7</td>
<td>4/5 (80)</td>
</tr>
<tr>
<td>Control</td>
<td>5</td>
<td>3/2</td>
<td>70.6/68±7.8</td>
<td>2/5 (40)</td>
</tr>
<tr>
<td><strong>Urothelial</strong></td>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPC</td>
<td>2</td>
<td>1/1</td>
<td>69.4/71±5.9</td>
<td>1/2 (50.0)</td>
</tr>
<tr>
<td>Control</td>
<td>5</td>
<td>4/1</td>
<td>77.0/76±6.8</td>
<td>1/5 (20.0)</td>
</tr>
</tbody>
</table>

GI, gastrointestinal; LN, lymph node; M/F, male/female; MPC, micropapillary carcinoma.
Patient ages are presented as the mean/median ± std. dev.
**Table 2.** Primary antibodies used

<table>
<thead>
<tr>
<th>Target</th>
<th>Product name</th>
<th>Species/type</th>
<th>Source</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCT1</td>
<td>ab204348</td>
<td>Rabbit/poly</td>
<td>Abcam*</td>
<td>1:40</td>
</tr>
<tr>
<td>ASCT2</td>
<td>ab84903</td>
<td>Rabbit/poly</td>
<td>Abcam</td>
<td>1:800</td>
</tr>
<tr>
<td>GLUT1</td>
<td>ab15309</td>
<td>Rabbit/poly</td>
<td>Abcam</td>
<td>1:200</td>
</tr>
<tr>
<td>GLUT2</td>
<td>ab85715</td>
<td>Mouse/mono</td>
<td>Abcam</td>
<td>1:50</td>
</tr>
<tr>
<td>LAT1</td>
<td>Anti-Human LAT1 Polyclonal Antibody</td>
<td>Rabbit/poly</td>
<td>Transgenic**</td>
<td>1:50</td>
</tr>
<tr>
<td>SNAT1</td>
<td>ab60145</td>
<td>Rabbit/poly</td>
<td>Abcam</td>
<td>4 µg/ml</td>
</tr>
</tbody>
</table>

*Abcam, Cambridge, UK. **Transgenic, Kumamoto, Japan.
<table>
<thead>
<tr>
<th>Transporter</th>
<th>Type</th>
<th>Mean</th>
<th>SD*</th>
<th>SE** of the mean</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCT1</td>
<td>MPC</td>
<td>5.31</td>
<td>6.404</td>
<td>1.189</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td>CONT</td>
<td>1.66</td>
<td>2.404</td>
<td>0.425</td>
<td></td>
</tr>
<tr>
<td>ASCT2</td>
<td>MPC</td>
<td>6.69</td>
<td>5.245</td>
<td>0.974</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>CONT</td>
<td>2.50</td>
<td>3.302</td>
<td>0.584</td>
<td></td>
</tr>
<tr>
<td>GLUT1</td>
<td>MPC</td>
<td>12.86</td>
<td>7.120</td>
<td>1.322</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>CONT</td>
<td>5.28</td>
<td>5.069</td>
<td>0.896</td>
<td></td>
</tr>
<tr>
<td>GLUT2</td>
<td>MPC</td>
<td>11.10</td>
<td>6.472</td>
<td>1.202</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>CONT</td>
<td>5.16</td>
<td>5.131</td>
<td>0.907</td>
<td></td>
</tr>
<tr>
<td>LAT1</td>
<td>MPC</td>
<td>4.14</td>
<td>6.828</td>
<td>1.268</td>
<td>0.211</td>
</tr>
<tr>
<td></td>
<td>CONT</td>
<td>2.34</td>
<td>3.525</td>
<td>0.623</td>
<td></td>
</tr>
<tr>
<td>SNAT1</td>
<td>MPC</td>
<td>9.28</td>
<td>6.708</td>
<td>1.246</td>
<td>0.106</td>
</tr>
<tr>
<td></td>
<td>CONT</td>
<td>6.59</td>
<td>6.069</td>
<td>1.073</td>
<td></td>
</tr>
</tbody>
</table>

**Figure Legends**

**Fig. 1.** The staining patterns of the transporters. Invasive MPCs with positive staining are shown (original magnification; 400×, scale bar = 40 µm). **a:** ASCT1: Linear staining along the basolateral membrane and faint cytoplasmic stain. **b:** ASCT2: Faint granular cytoplasmic stain. **c:** GLUT1: Intense membranous stain. **d:** GLUT2: Fine granular cytoplasmic stain. **e:** LAT1: Linear basolateral membranous stain. **f:** SNAT1: Coarse granular cytoplasmic stain.

**Fig. 2.** Comparison of transporter scores of the MPCs and non-MPCs. The average transporter score of each group was compared using Student's t-test or Welch's t-test, according to the homoscedasticity of the data. *p*<0.01.